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aBStraCt 
Introduction: The Acinetobacter calcoaceticus-baumannii (ABC) complex includes five species, and the A. baumannii is the 
most important of them because it carries mechanisms of carbapenems resistance, especially the oxacillinases. Objectives: 
The objectives of this study were to identify the species of the ABC complex, to evaluate the susceptibility profile and to investigate the 
presence of oxacillinases in carbapenems-resistant isolates from four Brazilian States. Methods: In the study period, 92 isolates from 
Rio Grande do Sul (RS), Rio de Janeiro (RJ), Paraná (PR) and São Paulo (SP) were collected. The isolates were identified by matrix-
assisted laser desorption ionization-time of fight mass spectrometry (MALDI-TOF MS) and sequencing of gyrB gene. Evaluation of 
susceptibility was performed by disk diffusion and broth microdilution. The presence of oxacillinases was performed by in-house 
multiplex polymerase chain reaction (PCR). Results: Ninety-one (99%) isolates were identified as A. baumannii by MALDI-TOF 
and sequencing. The majority of isolates (56; 61%) showed resistance to the six antimicrobial agents tested. Three isolates were 
resistant to polymyxin B [minimum inhibitory concentration (MIC) ≥ 4 μg/ml). Eighty (87%) isolates were positive to OXA-23-like, 
and twelve (13%) isolates to OXA-24-like. Conclusion: Our findings confirm the knowledge about the dissemination of the bla
OXA-23
 
gene in Brazil and suggest the recent emergence and spread of bla
OXA-24 
gene, since it was identified in three of the four sampled states. 
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introDuCtion
The Acinetobacter baumannii-calcoaceticus (ABC) complex 
includes the species A. baumannii, A. calcoaceticus, A. pittii, 
A. dijkshoorniae and A. nosocomialis(1, 2). The conventional 
methods used in the routine laboratory are unable to distinguish 
between ABC species. Recently, the mass spectrometry matrix-
assisted laser desorption ionization-time of fight mass 
spectrometry (MALDI-TOF MS) was implemented in clinical 
microbiology laboratory for identification of specie level(3). 
The ABC complex has become increasingly important due to 
the carbapenems resistance mainly associated with production 
of carbapenemases. This isolates have been reported in many 
regions of the world associated with high morbidity and 
mortality(4). 
The most prevalent carbapenemase in A. baumannii are 
OXA-carbapenemases, and the less frequently metallo-beta-
lactamases. The OXA-carbapenemases already identified in the 
ABC complex are divided into 6 subfamilies: OXA-51-like, OXA-23-
like, OXA-24-like, OXA-58-like, OXA-143 and OXA-235. In Brazil, 
strains producing enzymes of all these families have already been 
reported, except the OXA-235(5, 6). The aim of this study was to 
evaluate the susceptibility profile and to determine the prevalence 
of oxacillinases in carbapenems-resistant ABC isolates from four 
Brazilian states: Rio Grande do Sul (RS), Rio de Janeiro (RJ), 
















From July 2013 to October 2013 a total of 92 ABC isolates 
resistant to imipenem and meropenem were recovered as follows: 31 
(34%) isolates from Porto Alegre (RS), 28 (30%) from Rio de Janeiro 
(RJ), 21 (23%) from Curitiba (PR), and 12 (13%) from São Paulo 
(SP). Only one isolate from each patient was included in this study.
Identification of species of the ABC complex
The isolates were first identified by the Vitek® II system 
(BioMérieux, France). MALDI-TOF MS system (Bruker Biotyper® 
system – version 3.1) and gyrB gene sequencing were performed 
to confirm the identification at the specie level. To perform MALDI-
TOF, a bacterial colony was placed in the polymeric matrix and 
inserted into the machine. The results were interpreted according 
to the manufacturers’ recommendations. PCR amplification of 
gyrB was performed with a Applied Biosystems® Veriti® 96-Well 
Fast Thermal Cycler by using PCR reaction 5X Phusion HF buffer 
each one containing deoxynucleoside triphosphates 1.0 µl, 
primers at a concentration of 10 pmol/µl, deoxyribonucleic acid 
(DNA) 2.6 µl and 0.5 µl Phusion DNA polymerase (Perkin-Elmer) 
in a total volume of 50 µl(7). A total of 35 amplification cycles 
were performed with denaturation of DNA template at 98ºC for 
10 s, annealing at 57ºC for 30 s and extension at 72ºC for 10 min. 
Amplified products were purified by using QIAquick® (Qiagen) for 
sequencing.  The sequences produced were compared with those 
available on the GenBank and subsequently aligned using the 
BioEdit software version 7.1.3.
Susceptibility profile
The antimicrobial susceptibility profile was performed by 
disk diffusion for amikacin, Ampicillin/sulbactam, cefepime, 
ceftazidime, piperacillin/tazobactam, gentamicin (Oxoid®) and 
by broth microdilution to polymyxin B and tigecycline. The results 
were interpreted according to Clinical and Laboratory Standards 
Institute (CLSI) 2016, except for tigecycline wich we used the 
European Committee on Antimicrobial Susceptibility Testing 
(EUCAST). The chi-square test or Fisher’s exact test was used to 
statistical analyses with significance at 5% (p ≤ 0.05).
Oxacillinases genes











) were evaluated by 
multiplex polymerase chain reaction (PCR) using specific primers 
as previously described(8).
rESuLtS
Identification of species of the ABC complex
According to gyrB gene sequencing, all isolates were identified 
as A. baumannii. MALDI-TOF Bruker® correctly identified 91 
(99%) isolates (score > 2.0) as A. baumannii. One isolate (1%) 
had inconclusive result.
Susceptibility profile
The majority of isolates (56; 61%) showed resistance to the 
six antimicrobial agents tested. However, some differences among 
the states were identified: the isolates from São Paulo (SP) 
were less resistant to gentamicin (16.7%; p = 0.001); isolates 
from Rio Grande do Sul (RS) were more resistant to amikacin 
(51.6%; p = 0.005) and isolates from Rio de Janeiro (RJ) were 
more resistant to ceftazidime (75%; p = 0.023) (Table). Three 
isolates were resistant to polymyxin B [minimum inhibitory 
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was identified in all isolates; 80 (87%) of the 
isolates presented bla
OXA-23-like
. It was also possible to identify 12 
(13%) isolates producing bla
OXA-24-like 
from Rio Grande do Sul (RS), 




genes were not detected (Table).
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taBLE − Resistance profile and distribution of oxacillinase genes among  
A. baumannii isolates from four Brazilian States
Antibiotic RS (n = 31) RJ (n = 28) SP (n = 12) PR (n = 21) Total (n = 92) 
Amikacin 16 (51.6)a 17 (60.7) 11 (91.7) 19 (90.5) 63 (68.5)
Ampicillin/
sulbactam 31 (100) 25 (84.3) 11 (91.7) 21 (100) 88 (95.6)
Cefepime 30 (96.8) 24 (85.7) 12 (100) 19 (90.5) 84 (91.3)
Ceftazidime 26 (83.9) 21 (75) 12 (100) 21 (100) 80 (86.9)
Piperacillin/
tazobactam 31 (100) 28 (100) 12 (100) 21 (100) 92 (100)
Gentamicin 20 (64.5) 14 (50) 2 (16.7) 18 (85.7) 54 (58.7)




30 (99) 28 (100) 9 (75) 13 (62) 80 (87)
bla
oxa-24-like
1 (3.2) 0 3 (25) 8 (38) 12 (13)
a: number (percentage) of isolates presenting resistance; b: MIC50/MIC
90
 to polymyxin (µg/ml); 
c: all isolates were positive for bla
oxa-51-like 







RS: Rio Grande do Sul; RJ: Rio de Janeiro; SP: São Paulo; PR: Paraná; MIC: minimum 
inhibitory concentration.
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The main enzyme associated with carbapenem resistance 
in A. baumannii isolates is OXA-23(5). In this study, the four 
Brazilian states confirmed the high prevalence of OXA-23 associate 
with carbapenems resistance. This finding corroborate data 
already reported in a study that evaluated the spread of OXA-23 
in five geographic regions in Brazil, in which the prevalence 
of carbapenems-resistant OXA-23-positive A. baumannii was 
94.2%(12). 
In addition, 12 (13%) isolates were identified as OXA-24-like-
producing strains from three states [Rio Grande do Sul (RS), 
Paraná (PR), and São Paulo (SP)] suggesting the beginning of 
spread of this gene in Brazil. To date, there are few reports of OXA-
24/40-like in Brazil, but they are all associated with the multidrug 
resistance phenotype(13, 14). 
In conclusion, we observed high rates of antimicrobial 
resistance and dissemination of OXA-23 in all evaluated states. 
Furthermore it should be noted that this report evidences the 
dissemination of the enzyme OXA-24-like in different Brazilian 
states, suggesting the emergence of this novel type of enzyme in 
A. baumannii strain in our country.
DiSCuSSion
The species prevalence and the resistance profile of the 
ABC complex may vary according to the geographic region. 
However, A. baumannii is the most common specie associated 
with nosocomial infections and high resistance to carbapenems 
worldwide(9). In this study, all isolates were confirmed as 
A. baumannii by the methods used (MALDI-TOF and gyrB 
sequencing) and MALDI-TOF proved to be a quick and easy 
method for the identification of A. baumannii compared to the 
molecular method, obtaining high agreement score, as already 
reported(10).
In our study, two isolates of A. baumannii presented 
polymyxin MIC of 8 mg/ml and one isolate showed MIC of 
4 mg/ml which are considered resistant to polymyxin. Despite the 
low prevalence of polymyxin resistance in our study, phenotypes 
related to polymyxin resistance are worrisome as they may 
impair antimicrobial therapy(11). On the other hand, high rates 
of antimicrobial resistance were observed in the four states and 
this situation highlights the few therapeutic options to treat severe 
infections cause of A. baumannii(2, 4).
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